CTLA4 and cancer: Despite somewhat different phenotypes, both CTLA‐4 and PD‐1 pathways have been targeted in cancer immunotherapy with remarkable efficacy against a range of tumours (Sharma & Allison, 2015; Ribas & Wolchok, 2018).